Detailansicht

Wissensnetz

Person

Udo Holtick (1973-)

Arzt

Name	Udo Holtick
Zeit	1973- (Lebensdaten)
Beruf	Arzt (charakteristischer Beruf)
Weitere Angaben	Arzt
Datensatztyp	Person
GND-Nummer	12908011X
Datensatz-ID	12908011X
Beteiligt an alle anzeigen Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience Mobilization and hematopoietic stem cell collection in poor mobilizing patients with lymphoma: final results of the german OPTIMOB study Mocravimod, a selective S1PR modulator in allogeneic hematopoietic stem cell transplantation for malignancy Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience High mortality of COVID-19 early after allogeneic stem cell transplantation: a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group Psychische Komorbidität und poststationäre Behandlungsadhärenz bei Patienten nach allogener hämatopoetischer Stammzelltransplantation S235: A two-part, single- and two-arm randomized, open-label study to evaluate the safety, tolerability and pharmacokinetics of the S1P receptor modulator KRP203 in subjects with hematological malignancies Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysis Elotuzumab in Kombination mit Pomalidomid und Dexamethason bei Multiplen Myelom Die Rolle des JAK-, STAT-Signalweges beim Hodgkin-Lymphom

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Udo Holtick (1973-)

Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease

Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study

Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience

Mobilization and hematopoietic stem cell collection in poor mobilizing patients with lymphoma: final results of the german OPTIMOB study

Mocravimod, a selective S1PR modulator in allogeneic hematopoietic stem cell transplantation for malignancy

Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease

Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease

Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience

High mortality of COVID-19 early after allogeneic stem cell transplantation: a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Psychische Komorbidität und poststationäre Behandlungsadhärenz bei Patienten nach allogener hämatopoetischer Stammzelltransplantation

S235: A two-part, single- and two-arm randomized, open-label study to evaluate the safety, tolerability and pharmacokinetics of the S1P receptor modulator KRP203 in subjects with hematological malignancies

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Bridging antifungal prophylaxis with 50 mg or 100 mg micafungin in allogeneic stem cell transplantation: A retrospective analysis

Elotuzumab in Kombination mit Pomalidomid und Dexamethason bei Multiplen Myelom

Die Rolle des JAK-, STAT-Signalweges beim Hodgkin-Lymphom